Bronchodilator/bronchoprotective effects of aclidinium bromide, a novel long-acting anticholinergic: a phase I study Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
The preclinical urinary and renal safety profile of aclidinium bromide, a novel long-acting anticholinergic drug Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Low systemic exposure to aclidinium bromide, a novel long-acting anticholinergic, after multiple doses Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Aclidinium bromide, a novel long-acting anticholinergic drug, has a good preclinical cardiovascular safety profile Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Once-daily administration of aclidinium bromide, a novel, long-acting anticholinergic: a phase II, dose-finding study Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Safety and pharmacokinetics of aclidinium bromide, a novel, long-acting muscarinic antagonist, in renally impaired subjects Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
The efficacy of long-acting anticholinergic agent, tiotropium bromide on dynamic hyperinflation in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2 -adrenoreceptor agonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Absolute bioavailability of inhaled aclidinium bromide and safety and tolerability of aclidinium bromide administered intravenously in healthy subjects Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
Aclidinium bromide, a novel long-acting anticholinergic, does not affect QT interval in healthy subjects Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Investigation of the enzymatic hydrolysis of aclidinium bromide in human plasma Source: Annual Congress 2009 - New bronchodilators Year: 2009
The potential cost-effectiveness of glycopyrronium bromide, a novel LAMA Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012
Effect of aclidinium bromide, a novel long-acting anticholinergic, on salivation, colonic motility and faecal output in different animal models Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Monitoring of nasal permeability during the treatmrnt of patients with overlap syndrome with combined broncholytic drug (ipratropium bromide + salbutamol) Source: Eur Respir J 2001; 18: Suppl. 33, 216s Year: 2001
Evaluation of bronchodilator response to single dose tiotropium bromide Source: Eur Respir J 2004; 24: Suppl. 48, 504s Year: 2004
Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016